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INTRODUCTION
Acute kidney injury (AKI) is a common clinical syndrome 
that has been the focus of several recent studies. It is 
important in terms of hospital mortality, renal replacement 
rates, cost and duration of hospitalization, and mortality 
in patients with end-stage renal disease. Accordingly, 
current research is aimed at identifying means to reduce 
both the incidence of AKI (primary prevention) and its 
frequently adverse prognosis in patients with the disease 
(secondary prevention). The results of animal studies 
indicate that AKI progression is reversible by appropri-
ate interventions implemented in the early stages of the 
disease [1,2]. This finding has prompted interest in 
identifying diagnostic biomarkers for early AKI. Serum 
cystatin C and urine neutrophil gelatinase-associated 
lipocalin (NGAL), kidney injury molecule (KIM)-1, and 
interleukin (IL)-18, among others, have been shown to 
predict early AKI.
The pathogenesis of AKI is complex and its prognosis 
varies markedly depending on the underlying cause. For 
example, there are several critical diseases associated 
with AKI, and the degree of increase in serum creatinine 
levels has been related to serious adverse events, including 
high hospital mortality rates and dialysis dependence. 
The BEST study reported that 13.8% of surviving AKI 
patients still required dialysis after they were discharged 
from the intensive care unit (ICU), while patients with 
fewer complications had less impairment of renal function 
and a better prognosis [3]. In a study of 2,672 patients 
who had received coronary bypass surgery, the incidence 
of AKI was 8%, and only 8.7% of these patients required 
dialysis (based on the diagnostic standard for AKI of 
serum creatinine levels > 1 mg/dL over baseline) [4]. Thus, 
it is obvious that not all AKI patients require the same 
kind and intensity of treatment, and effective clinical 
decision-making accordingly requires stratification of 
AKI’s adverse prognosis. In addition, despite the revers-
ible nature of clinical AKI, defined as the restoration of 
normal serum creatinine, persistent injury remains a pos-
sibility, carrying with it long-term adverse outcomes [5]. 
Studies have shown that tubular injury, renal hemody-
namics, and inflammation/oxidative stress are all involved 
in AKI and in subsequent renal repair processes [6]. 
Therefore, the identification of biomarkers reflecting the 
characteristics of these pathophysiological stages would 
provide prognostic information for AKI patients. This 
review describes our current understanding of urinary 
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biomarkers that may predict the prognosis of patients 
with AKI.
BIOMARKERS OF SHORT-TERM PROGNOSIS
NGAL
NGAL is a classic biomarker for both the early diagnosis 
and short-term outcome of AKI. Although the relation-
ship between NGAL and the course of AKI is not well 
understood, the protein is known to play a role in promot-
ing growth and differentiation in renal repair processes 
[7,8] and in the response to focal renal oxidative stress 
[9]. Both serum and urinary NGAL serve as reliable 
biomarkers in the detection of AKI, whereas only urinary 
NGAL is able to predict the need for renal replacement 
in children with diarrhea-associated hemolytic uremic 
syndrome [10]. However, in children undergoing cardiac 
surgery, plasma NGAL levels strongly correlate with the 
duration and severity of AKI and with length of hospital 
stay [11]. It should be noted that NGAL assay may be 
influenced by several coexisting conditions, such as 
chronic disease, hypertension, systemic infections, and 
inflammation. While the resulting disturbances in plasma 
NGAL levels are small compared to the effect of AKI on 
the protein itself, they are sufficient to exclude heteroge-
neous patient populations from AKI biomarker studies. 
Thus, NGAL was evaluated to be a prognostic biomarker 
in homogeneous patient populations with strict inclusion 
criteria, mostly in the pediatric population (Table [12–14]). 
Therefore, currently, the utility of NGAL in predicting 
the outcomes of patients with AKI is mixed and depends 
on the clinical setting.
Cystatin C
The cysteine protease inhibitor cystatin C is produced by 
nearly all human cells and released into the bloodstream. 
Due to its low molecular mass (13 kDa), the protein is 
freely filtered by the renal glomerulus and then metabo-
lized by the proximal tubule. Increased levels of serum 
cystatin C indicate impaired renal function in AKI pa-
tients and, together with serum creatinine, are associated 
with a greater likelihood of renal replacement therapy 
and death [15]. In nonoliguric acute tubular necrosis 
(ATN), increased urinary excretion of cystatin C may 
predict the requirement for renal replacement therapy 
[16]. However, the prognostic value of cystatin C in 
serum is controversial. In the ICU, increases in serum 
cystatin C levels ≥ 50% are moderately predictive of the 
need for renal replacement therapy [17], while another 
ICU study showed weak predictive power of serum 
cystatin C with respect to hospital mortality [18].
KIM-1
KIM-1 is a type 1 transmembrane protein whose ex-
pression is markedly upregulated in the proximal tubule 
in the AKI rat model. Urinary KIM-1 levels are sig-
nificantly higher in patients with ischemic ATN than in 
patients without ATN. In a multivariate model, a one-
unit increase in normalized KIM-1 was associated with 
a greater than 12-fold risk for the presence of ATN [19]. 
In hospitalized patients with AKI, urinary KIM-1 can 
predict adverse clinical outcomes, including dialysis 
requirement and hospital death [20].
IL-18
The recruitment of neutrophil infiltration by IL-18 ac-
counts for the cytokine’s deleterious role in an AKI 
model in ischemic mice [21]. Urinary IL-18 levels have 
been reported to predict mortality in ICU patients [22]. 
In a matched case-control study involving patients who 
underwent cardiopulmonary bypass (CPB) surgery, 
urinary IL-18 levels were independently associated with 
AKI duration [14]. However, in studies of unmatched 
design, urinary IL-18 levels did not aid in the diagnosis 
of AKI in adult patients following CPB surgery [23,24]. 
This discrepancy between the diagnostic and prognostic 
ability of urinary IL-18 was also observed in a critically 
ill adult population, in which urine IL-18 did not predict 
AKI development in some settings but was predictive 
of poor clinical outcome [25].
NOVEL CANDIDATE PROGNOSTIC BIOMARKERS
Liver fatty acid binding protein (L-FABP) is an intercel-
lular lipid chaperone protein that selectively combines 
with unsaturated free fatty acids and lipid peroxides 
Table. Neutrophil gelatinase-associated lipocalin as a prognostic biomarker in short-term prognosis of acute kidney injury in children
Inclusion criteria Exclusion criteria Definition of short-term outcomes Reference
Children with CPB Nephrotoxin use AKI duration; AKI severity; hospital 12
   stay; RRT; death
Children in ICU with mechanical RRT AKI duration 13
 ventilation and bladder catheterization
Children with CPB Renal insufficiency, diabetes,  AKI duration 14
  PVD, and nephrotoxin use
CPB = cardiopulmonary bypass; AKI = acute kidney injury; RRT = renal replacement therapy; ICU = intensive care unit; PVD = periph-
eral vascular disease.
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under conditions of hypoxia. According to one report, 
both urine and serum L-FABP levels are elevated after 
cardiac surgery. The former was shown to increase ear-
lier than the latter, suggesting that L-FABP is produced 
locally in the kidneys [26]. A cross-sectional study ex-
amining urine L-FABP levels in 92 AKI patients and 68 
controls (including cardiovascular and ICU patients and 
volunteers) found that the diagnostic value of urine L-
FABP for AKI is similar to that of NGAL, KIM-1 and 
N-acetyl-β-(D)-glucosaminidase, but greater than that 
of urine IL-18. Urine L-FABP levels could predict both 
the need for renal replacement and the combined endpoint 
of renal replacement and death [27].
Netrin-1 was shown to be involved in renal tubular 
epithelial cell proliferation and migration in a renal 
ischemia-reperfusion model [28]. The secretion of urine 
netrin-1 peaks 6 hours after CPB surgery. After 2, 6 and 
12 hours, the AUC of urine netrin-1 in the diagnosis of 
AKI is 0.74, 0.86 and 0.89, respectively. Six hours post-
operatively, urine netrin-1 levels reportedly correlate with 
the severity of AKI and the length of hospitalization [29]. 
That study, however, consisted of only 26 AKI patients 
and 34 controls and did not assess the clinical value of 
urine netrin-1 in AKI risk stratification.
Hypoxia-inducible factor-α (HIF-α) is a key cellular 
transcription factor that, as its name suggests, responds to 
tissue hypoxia. It plays an important role in the develop-
ment of AKI and in recovery from the disease. Vascular 
endothelial growth factor-A and angiopoietin-2 are 
important factors expressed downstream of HIF-α. 
Different HIF-α isoforms have been related to different 
adverse prognoses of AKI, including dialysis, inhospi-
tal mortality, and mechanical ventilation. In addition, 
angiopoietin-2 was shown to positively correlate with 
inhospital mortality, the combined endpoint of dialysis 
and inhospital mortality, and the combined endpoint of 
mechanical ventilation, dialysis and inhospital mortal-
ity [30]. Given that HIF-α levels do not represent the 
extent of injury, downstream factors may better reflect 
the prognosis of patients with AKI. In addition, the re-
lationship between HIF-α, vascular endothelial growth 
factor-A and angiopoietin-2 has yet to be adequately ex-
plained [30]; therefore, it remains unclear as to whether 
the HIF-α system can be used as a biomarker with 
prognostic predictive power.
Advanced oxidation protein products (AOPP) are 
dityrosine-containing protein cross-linking products that 
have been used as indicators of free iron and uremia-
related inflammation/oxidative stress [31,32]. AOPP 
have been shown to accelerate the progression of renal 
disease [33]. Among ICU patients, AOPP levels in 
patients with severe AKI (RIFLE level F) are higher 
than in patients with less severe forms of the disease 
(RIFLE levels R and I), but AOPP levels cannot be used 
to identify patients suffering from AKI [34] and is of 
little prognostic value.
EVALUATING THE LONG-TERM PROGNOSIS: 
NEW CHALLENGES
According to the 2004 Acute Dialysis Quality Initiative, 
renal function following AKI is evaluated based on the 
serum creatinine value. The second Acute Dialysis 
Quality Initiative conference recommended a follow-up 
period of 60–90 days in the assessment of patients with 
AKI [6]. Consistent with this “acute injury” definition, 
several short-term predictors based on serum creatinine 
value have been used as endpoints in a number of stud-
ies of AKI biomarkers and disease prognosis, including 
the RIFLE or AKIN classification, renal function re-
covery time, inhospital mortality, renal replacement 
therapy, and length of hospitalization. The problem re-
mains that serum creatinine levels do not reflect the 
subclinical pathological changes that occur in the kidneys 
during AKI. Animal studies suggest that renal function 
does not recover completely after AKI and that sodium 
metabolic disorders, hypertension, and subsequent renal 
disease may ensue [35]. Epidemiological data have shown 
that even if serum creatinine levels return to normal after 
injury, the long-term risk of chronic renal disease, renal 
failure and death is still higher in AKI patients than in 
those without AKI [5,36]. Therefore, viable prognostic 
biomarkers should also include indicators of chronic 
renal disease secondary to AKI. For example, albumin-
uria is a traditional indicator of impaired glomerular 
filtration function, which in turn is a recognized marker 
of progressive chronic renal disease. In recent years, 
some researchers have concluded that albuminuria is the 
result of renal tubular injury [37,38]. Since tubulointer-
stitial damage is the primary type of damage associated 
with AKI, albuminuria may be useful in predicting the 
long-term prognosis of these patients.
POSSIBLE FUTURE DIRECTIONS
Since not all biomarkers fulfill the bifunctional role of 
diagnosis and prognosis, some studies have attempted to 
measure several specific “complementary” biomarkers 
in a combined approach. A recent nested case-control 
study conducted on a group of 122 patients who under-
went CPB surgery detected urine KIM-1 and IL-18 si-
multaneously and found that the former marker had an 
early diagnostic value while the latter marker predicted 
AKI progression. The two biomarkers were statistically 
combined in a multiple logistic regression analysis to 
predict the progression of AKI. The areas under the ROC 
were 0.833 and 0.902 at 6 and 12 hours, respectively [24]. 
Although this method has not been widely used and is not 
convenient for clinical practice, the results suggest that 
combining indicators with different functions or 
strengths is beneficial until biomarkers with “dual func-
tion” have been identified. Furthermore, commercial 
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multimarker assay kits are needed for simple and rapid 
determinations of AKI, as well as those easy kits in 
emergency and cancer medicine settings [39,40].
At present, there are no studies on the long-
term prognostic stratification of AKI. Clinically, urine 
albumin and traditional markers of tubulointerstitial 
injury such as β2-microglobulin and N-acetyl-β-(D)-
glucosaminidase are typically selected as markers of 
chronic kidney injury secondary to AKI. This strategy 
is empirically based because the relationship between 
these markers and long-term adverse prognosis is not 
necessarily the same in acute as in chronic renal disease. 
Instead, biomarkers that are specific to renal repair 
mechanisms may better predict the long-term prognosis 
of AKI and further investigations to identify such mark-
ers are certainly warranted.
CONCLUSION
Urine NGAL appears to be not only diagnostic of AKI 
but also indicative of the disease’s short-term prognosis; 
however, the accuracy of this biomarker must still be 
confirmed in different AKI settings. The remaining bio-
markers identified to date lack the dual function of diag-
nostic and prognostic stratification. The most feasible 
choice is therefore to combine the predictive functions 
of several markers to diagnose AKI and to predict the 
short-term prognosis of these patients. The lack of 
convenient multimarker assay kits for clinical practice 
is problematic, while biomarkers that predict the long-
term prognosis of AKI patients are as yet unknown.
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